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Abstract Inhibitors of the protease dipeptidyl peptidase IV
(DPP-IV) are promising new drugs for the treatment of type
2 diabetes. They are thought to act by inhibiting the
breakdown of glucagon-like peptide-1 and, thereby, selec-
tively enhancing insulin release under conditions when it is
physiologically required. These drugs are selective for
DPP-IV, but the enzyme itself has a broad range of
substrates other than glucagon-like peptide-1. Other high
affinity substrates of DPP-IV including peptide YY may
also play a role in the regulation of energy homeostasis.
Moreover, DPP-IV is also known as CD26 and considered
to be a moonlighting protein because it has a wide range of
other functions unrelated to energy homeostasis, e.g. in
immunity. The potential role of DPP-IV inhibition on
substrates other than glucagon-like peptide-1 in diabetes
patients remains to be elucidated.
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Glucagon-like peptide-1 (GLP-1) is a hormone which is
released following meals and stimulates insulin release
from the pancreas. Its effects are terminated by breakdown
by the enzyme dipeptidyl peptidase IV (DPP-IV). There-
fore, inhibition of DPP-IV increases GLP-1 levels in the
circulation and, hence, insulin release under conditions
when it is needed, i.e. after a meal but not during fasting.
Consequently, inhibition of GLP-1 inactivation is an
insulinotropic principle which is unlikely to cause hypo-
glycaemia between meals. The lower risk for hypo-
glycaemic events as compared with other insulinotropic or
insulin-sensitising agents makes DPP-IV inhibitors very
promising candidates for a more physiological treatment of
type 2 diabetes (Combettes and Kargar 2008).
In recent years, a number of selective DPP-IV
inhibitors such as vildagliptin and sitagliptin have been
evaluated in clinical trials (Hermansen et al. 2007;
Utzschneider et al. 2008) and may have a future role in
the treatment of type 2 diabetes (Combettes and Kargar
2008). In this issue of the journal, a novel DPP-IV
inhibitor, ASP8497, is being introduced, which is highly
selective for DPP-IV as compared to other peptidases
(Someya et al. 2008). However, DPP-IV itself is not
selective for GLP-1 but has a wide range of other natural
substrates (Boonacker and Van Noorden 2003). Therefore,
we wish to highlight potential implications of this lack of
selectivity of DPP-IV for the use of DPP-IV inhibitors in
diabetes treatment.
Another high affinity substrate of DPP-IV is peptide YY
(PYY; Mentlein et al. 1993). Whereas cleavage of GLP-1
by DPP-IV causes inactivation, cleavage of PYY yields the
long C-terminal fragment PYY3–36, which is inactive at
some but active at other subtypes of PYY receptors.
Specifically, it converts the non-subtype-selective agonist
PYY into a selective agonist at Y2 and Y5 receptors
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(Michel et al. 1998). Thus, DPP-IV does not inactivate
PYY but, rather, qualitatively alters its biological activity.
Indeed it has been reported that peripherally adminis-
tered PYY3–36 inhibits food intake in rats, whereas PYY is
a potent central stimulator of food intake (Batterham et al.
2002). Given the role of obesity in type 2 diabetes,
prevention of the formation of such an endogenous food
intake inhibitor by a DPP-IV inhibitor may be undesirable.
It has been proposed that the effects of peripherally
administered PYY3–36 on central nervous functions such
as food intake may be mediated by excitation of afferent
vagal fibres (Koda et al. 2005). However, the majority of
subsequent rodent studies did not confirm inhibition of food
intake by PYY3–36, particularly not following chronic
administration (Boggiano et al. 2005). On the other hand,
recent studies in non-rodents such as pigs (Ito et al. 2006)
or humans (Degen et al. 2005; Sloth et al. 2007a; Sloth et
al. 2007b) have reported reduced food intake upon
peripheral administration of PYY3–36 but typically, these
effects were found only at relatively high concentrations.
Moreover, the effect of PYY3–36 on food intake was
biphasic, depending on the duration of its administration
(Parkinson et al. 2008). Two additional findings deserve
consideration. Firstly, PYY3–36 was reported to promote
fat oxidation and ameliorate insulin resistance in mice even
under conditions of chronic administration where it did not
reduce food intake (van den Hoek et al. 2006). Secondly,
PYY3–36 was reported to lower plasma glucose levels even
in the absence of alterations in circulating insulin levels
(Bischoff and Michel 1998).
Taken together, the presently available data on PYY3–36
on food intake and metabolic parameters are not yet
conclusive. However, it is clear that PYY3–36 is largely
formed by DPP-IV, raising the possibility that selective
DPP-IV inhibitors may exert part of their effects by
modulating the PYY/PYY3–36 ratios. Therefore, it remains
to be explored how possible effects on PYY cleavage
contribute to metabolic effects of DPP-IV inhibitors in
diabetic patients.
Moreover, DPP-IV is not only a protease for substrates
relevant to energy homeostasis, but it also has a range of
additional functions (Boonacker and Van Noorden 2003).
Therefore, it is considered to be a moonlighting protein. As
a protease, it has several other substrates, and it also acts as
a receptor and costimulatory protein in the immune system.
In this regard, CD26 is considered to be an important
regulator of T-cell function (Reinhold et al. 2008). These
pleiotropic effects of DPP-IV or CD26 lead to numerous
potential uses of its inhibitors other than type 2 diabetes
including inflammatory diseases (Ohnuma et al. 2006;
Reinhold et al. 2007; Thielitz et al. 2008; Thompson et al.
2007) and, perhaps, certain types of cancers (Kikkawa et al.
2005; Thompson et al. 2007). Some of these effects may
manifest as useful secondary actions when being used for
the treatment of diabetic patients whereas others may
manifest as adverse events. Most of these potential
additional effects may not yet have manifested in the
currently published diabetes literature, but it appears
prudent to keep an eye on them.
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